Preliminary results promising for intraoperative wavefront measurement of LRI effect

Article

Initial experience with intraoperative use of a wavefront analyzer (WaveTec Visions Systems) suggests that it may be a very useful tool for achieving increased accuracy and efficiency in astigmatism correction.

Initial experience with intraoperative use of a wavefront analyzer (WaveTec Visions Systems) suggests that it may be a very useful tool for achieving increased accuracy and efficiency in astigmatism correction, said James E. McDonald II, MD.

The device has a very small footprint and attaches to the surgical microscope. Based on Talbot moiré interferometry, it provides real-time analysis of both low and high order aberrations with a resolution of < 0.1 D.

The technology is being evaluated in a multicenter study. Dr. McDonald presented results from a series of 29 patients who underwent cataract surgery with IOL placement and limbal relaxing incisions (LRIs). Wavefront measurements were obtained prior to the phaco incision, after IOL implantation, and after the LRIs. The evaluations added only 1 to 2 minutes to the OR time.

Patients were re-'evaluated at 3, 6, and 13 weeks postoperatively, and the analyses showed very strong correlations between the real-time wavefront measurements and the postoperative manifest refractive change and corneal topography.

"In a retrospective review of 191 IOL implantation cases among six surgeons, we found less than 65% of eyes were within 0.5 D of targeted refraction and 1 out of 20 were off by as much 1.0 D. These types of outcomes create a challenge as we present premium lenses to our patients," said Dr. McDonald.

"We are very encouraged by our initial experience with this technology for intraoperative measurements because it suggests it may move us forward toward our goal of better postoperative outcomes."

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.